Marksans Pharma Ltd
Pharmaceuticals & Biotechnology | Small Cap
Marksans Pharma Ltd demonstrates a mixed financial performance. The company shows strong liquidity and solvency, indicating a solid ability to meet its short-term and long-term obligations. Growth is robust, driven by strong revenue and profit increases. Profitability metrics are also excellent, reflecting efficient operations and healthy margins. However, efficiency ratios are weak, suggesting challenges in asset utilization. Financial ratios also need improvement, particularly in earnings per share, dividend, and capital expenditure management. Overall, while the company exhibits financial stability and growth potential, there are areas where operational efficiency and financial management could be enhanced. The company should focus on improving its asset turnover and managing capital expenditures more effectively to improve long-term financial health.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio3.80
- Profitability Ratio10.00
- Efficiency Ratio3.00
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio8.80
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
Marksans Pharma Ltd demonstrates a mixed financial performance. The company shows strong liquidity and solvency, indicating a solid ability to meet its short-term and long-term obligations. Growth is robust, driven by strong revenue and profit increases. Profitability metrics are also excellent, reflecting efficient operations and healthy margins. However, efficiency ratios are weak, suggesting challenges in asset utilization. Financial ratios also need improvement, particularly in earnings per share, dividend, and capital expenditure management. Overall, while the company exhibits financial stability and growth potential, there are areas where operational efficiency and financial management could be enhanced. The company should focus on improving its asset turnover and managing capital expenditures more effectively to improve long-term financial health.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
39.11
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
28.16
P/B RATIO
3.89
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
3.99
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
16.23
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹259.67 as on Jun 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤14th Nov 25
Q2 FY26 Earnings Conference Call
BULLISH SENTIMENT
The company exhibits excellent growth, driven by strong revenue, operating profit, EPS, asset, and net income growth rates. This indicates the company is expanding its operations and profitability effectively. The company's prospects are very encouraging, reflecting its ability to capitalize on market opportunities and increase shareholder value. The company may be able to achieve higher growth rate in future.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.36 | 24.21 | 17.55 | 20.49 | 12.5 |
| Operating Profit Growth Rate | -23.82 | 31.27 | 35 | 15.25 | 13.61 |
| Earnings Per Share (EPS) Growth | -21.7 | 30.38 | 17.69 | 21.39 | 9.76 |
| Asset Growth Rate | 33.22 | 33.86 | 22.42 | 20.85 | 19.17 |
| Net Income Growth Rate | -21.76 | 41.71 | 18.87 | 21.59 | 9.66 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed picture. While adjusted and cash EPS are moderate, the book value per share is relatively low. Dividend per share and capital expenditures are also low, indicating potential areas for improvement in shareholder returns and investment strategies. The company may need to reassess its capital allocation decisions to enhance overall financial performance. Enhanced capital expenditure can improve efficiency and growth.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 4.61 | 5.87 | 7.02 | 8.56 | 9.38 |
| Cash Earnings Per Share (Cash EPS) | 5.66 | 7.04 | 8.64 | 10.36 | 11.53 |
| Book Value Per Share | 29.32 | 38.78 | 45.89 | 54.82 | 67.18 |
| Dividend Per Share (DPS) | 0.27 | 0.53 | 0.62 | 0.84 | 0 |
| Capital Expenditures (CapEx) | 46 | 54 | 208 | 172 | 130 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits excellent profitability, driven by high gross profit margin, ROCE, ROE, ROA, operating margin, and net margin. This indicates efficient operations and effective cost management. The company's returns on capital and equity are robust, reflecting its ability to generate profits from its investments. The company is in very good state in terms of profitability.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 14.35 | 15.55 | 17.68 | 17 | 17.01 |
| Return on Capital Employed (ROCE) | 23 | 22 | 21 | 20 | 19 |
| Return on Equity (ROE) | 15.56 | 15.19 | 15.25 | 15.52 | 13.89 |
| Return on Assets (ROA) | 15.83 | 15.53 | 17.12 | 16.33 | 15.57 |
| Operating Margin | 17.37 | 18.36 | 21.08 | 20.17 | 20.37 |
| Net Margin | 12.54 | 14.31 | 14.47 | 14.6 | 14.23 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios are generally low, indicating potential issues with asset utilization. Low turnover ratios and high days sales in inventory and receivable days suggest the company is not effectively managing its assets to generate revenue. This could result in higher carrying costs and lower profitability. Improving asset management practices is essential to enhance overall financial performance. Efficient asset management can reduce cost and increase revenue.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.48 | 3.81 | 2.81 | 2.67 | 2.71 |
| Inventory Turnover Ratio | 3.08 | 3.44 | 3.25 | 2.97 | 2.69 |
| Receivables Turnover Ratio | 4.47 | 4.56 | 5 | 5.28 | 4.98 |
| Days Sales in Inventory Ratio | 118.51 | 106.1 | 112.31 | 122.9 | 135.69 |
| Receivable Days | 81.66 | 80.04 | 73 | 69.13 | 73.29 |
| Capital Turnover Ratio | 1.17 | 1.01 | 0.95 | 0.95 | 0.88 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are excellent, demonstrating a strong ability to meet its interest and dividend obligations. The high interest coverage ratio indicates the company can easily cover its interest expenses. This provides financial flexibility and reduces the risk of default. The company is in very good state to pay off its debts.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 32 | 38.56 | 39.55 | 43 | 24.38 |
| Equity Dividend Coverage Ratio | 16.67 | 11.11 | 11.11 | 10 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company demonstrates excellent solvency, indicating a strong long-term financial stability. Low debt and high equity ratios suggest a conservative capital structure. The company relies more on equity than debt to finance its assets, reducing financial risk. This provides a solid foundation for future growth and stability. The company's ability to meet its long-term obligations is very secure, indicating financial resilience. The company's debt is very well managed and the company is growing well.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.05 | 0.04 | 0.09 | 0.11 | 0.09 |
| Debt to Equity Ratio | 0.05 | 0.04 | 0.1 | 0.12 | 0.1 |
| Equity Ratio | 0.95 | 0.96 | 0.91 | 0.89 | 0.91 |
| Debt To Asset Ratio | 0.04 | 0.04 | 0.08 | 0.09 | 0.08 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is generally strong, indicating a robust ability to meet its short-term obligations. High current, quick, and cash ratios reflect ample liquid assets. However, the operating cash flow ratio is relatively weak, suggesting a potential disconnect between earnings and operating cash flows. While the company can comfortably cover its immediate liabilities, generating more cash from operations could enhance its financial flexibility. The weighted average calculation gives more weight to recent performance, providing an accurate assessment of the current liquidity situation. The very high liquidity may also mean that the company is not efficiently using its assets to generate revenue.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 3.31 | 4.65 | 4.66 | 4.7 | 5.26 |
| Quick Ratio | 2.15 | 3.32 | 3.12 | 2.92 | 3.41 |
| Cash Ratio | 0.96 | 1.96 | 1.68 | 1.49 | 1.89 |
| Operating Cash Flow Ratio | 0.27 | 0.65 | 0.57 | 0.44 | 0.87 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 32.77 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 22.52 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 35.90 | Neutral | 369.00 | 19.44 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 37.30 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 28.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | Shilpa Medicare Ltd | 5.94 | 44.32 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 11 | Strides Pharma Science Ltd | 5.55 | 18.41 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | Jeena Sikho Lifecare Ltd | 5.52 | 31.22 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 14 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 15 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | Procter & Gamble Health Ltd | 3.45 | 31.71 | Neutral | 457.00 | 196.94 | 327.00 |
| 21 | Sanofi India Ltd | 3.45 | 18.59 | Neutral | 491.00 | 134.52 | 413.00 |
Marksans Pharma's management demonstrates mixed effectiveness. Strong sales and profit growth indicate capable leadership, while increasing institutional interest reflects confidence in the company's prospects. However, rising debt levels and a lengthening cash conversion cycle present challenges. Although strategic investments are evident, inefficiencies in working capital management raise concerns. Overall, management effectiveness is rated as Orange due to these counterbalancing factors.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Compounded Sales Growth (TTM) | 20% | Demonstrates strong revenue expansion |
| FII Holding (Mar 2025) | 22.19% | Indicates growing institutional confidence | |
| CONS | Cash Conversion Cycle (Mar 2025) | 247 days | Suggests inefficient working capital management |
| Borrowings (Mar 2025) | ₹ 322 Cr | Indicates increasing financial leverage |
Financial Performance & Growth
Marksans Pharma exhibits robust financial performance and growth. Compounded sales growth has consistently been positive, underscoring the company's ability to expand its revenue base. Profit growth also reflects increasing profitability.
| Metric | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| CAGR (%) Sales | 13.05% | 14.86% | 24.23% | 17.56% | 20.46% |
| CAGR (%) Profit | 5.18% | 23.32% | 34.76% | 18.85% | 21.52% |
Quarterly YOY sales growth has been consistently positive, ranging from 15.23% to 26.51%. Quarterly OPM has been maintained above 15%. This consistent growth in both sales and profits indicates effective management in driving financial performance.
Capital Efficiency & Returns
Marksans Pharma demonstrates reasonable capital efficiency and returns. ROCE and ROE indicate the company's effectiveness in utilizing capital and generating returns for shareholders.
| Metric | Mar 2014 | Mar 2017 | Mar 2020 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | 37% | 4% | 25% | 22% | 21% | 20% |
ROCE has generally remained positive, although there has been some fluctuation over the years. ROE has been reasonably consistent. These metrics suggest that the company is utilizing its capital to generate profits. The cash conversion cycle is long, indicating inefficient working capital management.
Financial Health & Prudence
Marksans Pharma's financial health and prudence present a mixed picture. Debt levels have increased in recent years, as reflected in the increasing borrowings.
| Metric | Mar 2014 | Mar 2017 | Mar 2020 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Borrowings (Cr) | 173 | 110 | 30 | 123 | 244 | 322 |
| Debt/Equity Ratio | 1.34 | 0.28 | 0.05 | 0.07 | 0.11 | 0.12 |
While the debt-to-equity ratio is still relatively low, the increasing borrowings indicate that the company is taking on more debt. The company consistently shares profits through dividends.
Strategic & Operational Indicators
Marksans Pharma shows mixed strategic and operational indicators. Working capital management reveals an increasing cash conversion cycle, which has risen from 118 days in 2014 to 247 days in 2025. This indicates a potential issue with operational efficiency, particularly in managing inventory and receivables. Investments in gross block and CWIP suggest strategic investments in growth-oriented assets. The gross block has increased significantly, indicating investments in fixed assets. However, the increasing cash conversion cycle raises concerns about working capital management efficiency.
Shareholding & Ownership Structure
Marksans Pharma has a reasonably stable shareholding and ownership structure. Promoter holding has decreased from 48.25% to 43.87% over the past several years.
| Metric | Mar 2017 | Mar 2020 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Promoter Holding (%) | 48.25 | 48.25 | 43.85 | 43.85 | 43.87 |
| FII Holding (%) | 8.35 | 2.54 | 15.11 | 15.57 | 22.19 |
| DII Holding (%) | 0.28 | 0.89 | 1.46 | 5.17 | 4.55 |
FII holdings have increased significantly, indicating growing institutional interest in the company. This suggests confidence in the company's future prospects. DII holdings have also increased, further supporting the positive sentiment.
Marksans Pharma faces moderate risks. Increasing debt levels and a lengthening cash conversion cycle present financial and operational challenges. Consistent sales and profit growth, along with rising institutional interest, provide some mitigation. The risk assessment is rated as Orange, indicating the need for monitoring.
Off-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposures for Marksans Pharma. Without this data, it is challenging to assess the potential financial risks and obligations that are not reflected on the company's balance sheet.
Contingent liability evaluation
There is no specific data available on contingent liabilities for Marksans Pharma. The absence of this data makes it difficult to assess potential financial risks and obligations. Therefore, the contingent liability evaluation is rated as Average due to the lack of available information.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10260.45Bearish
- SMA 20257.87Bullish
- SMA 50253.39Bullish
- EMA 10259.76Bearish
- EMA 20257.98Bullish
- EMA 50253.71Bullish
- DEMA 10260.98Bearish
- DEMA 20261.38Bearish
- DEMA 50259.74Bearish
- TEMA 10260.05Bearish
- TEMA 20261.96Bearish
- TEMA 50260.18Bearish
- MACD2.48Bearish
- ADX43.71Strong Trend
- IndicatorValueSignal
- RSI57.43Neutral
- CCI25.07Neutral
- ROC 9-0.58Bearish
- ROC 141.57Bullish
- ROC 254.57Bullish
- Stoch K49.72Neutral
- Stoch D59.75Neutral
- IndicatorValueSignal
- BB Upper267.39Neutral
- BB Middle257.87Neutral
- BB Lower248.35Neutral
- ATR3.06Low Volatility
- IndicatorValueSignal
- MFI71.62Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10259.48Bearish
- SMA 20254.29Bullish
- SMA 50248.54Bullish
- EMA 10258.46Bullish
- EMA 20255.69Bullish
- EMA 50249.14Bullish
- DEMA 10261.28Bearish
- DEMA 20260.27Bearish
- DEMA 50260.02Bearish
- TEMA 10261.37Bearish
- TEMA 20261.22Bearish
- TEMA 50259.15Bearish
- MACD3.52Bullish
- ADX43.97Strong Trend
- IndicatorValueSignal
- RSI61.51Neutral
- CCI65.79Neutral
- ROC 91.69Bullish
- ROC 144.80Bullish
- ROC 253.72Bullish
- Stoch K68.88Neutral
- Stoch D70.79Neutral
- IndicatorValueSignal
- BB Upper265.58Neutral
- BB Middle254.29Neutral
- BB Lower243.01Neutral
- ATR4.26Low Volatility
- IndicatorValueSignal
- MFI64.79Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10254.06Bullish
- SMA 20251.16Bullish
- SMA 50238.50Bullish
- EMA 10255.60Bullish
- EMA 20251.21Bullish
- EMA 50237.68Bullish
- DEMA 10260.03Bearish
- DEMA 20259.34Bearish
- DEMA 50260.01Bearish
- TEMA 10260.96Bearish
- TEMA 20258.96Bullish
- TEMA 50N/AN/A
- MACD6.07Bullish
- ADX63.13Strong Trend
- IndicatorValueSignal
- RSI65.00Neutral
- CCI123.59Overbought
- ROC 93.44Bullish
- ROC 144.44Bullish
- ROC 256.20Bullish
- Stoch K74.99Neutral
- Stoch D76.64Neutral
- IndicatorValueSignal
- BB Upper263.92Neutral
- BB Middle251.16Neutral
- BB Lower238.40Neutral
- ATR7.04Low Volatility
- IndicatorValueSignal
- MFI86.60Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10251.07Bullish
- SMA 20244.38Bullish
- SMA 50212.97Bullish
- SMA 100192.37Bullish
- SMA 200186.12Bullish
- EMA 10251.38Bullish
- EMA 20242.30Bullish
- EMA 50220.48Bullish
- EMA 100204.76Bullish
- EMA 200199.88Bullish
- DEMA 10259.28Bullish
- DEMA 20259.65Bullish
- DEMA 50246.25Bullish
- DEMA 100221.11Bullish
- DEMA 200198.54Bullish
- TEMA 10259.07Bullish
- TEMA 20260.65Bearish
- TEMA 50260.36Bearish
- TEMA 100241.41Bullish
- TEMA 200205.01Bullish
- MACD12.64Bearish
- ADX38.02Strong Trend
- IndicatorValueSignal
- RSI67.44Neutral
- CCI121.93Overbought
- ROC 148.79Bullish
- ROC 2528.60Bullish
- Stoch K83.25Overbought
- Stoch D74.60Neutral
- IndicatorValueSignal
- BB Upper268.39Neutral
- BB Middle244.38Neutral
- BB Lower220.37Neutral
- ATR11.61Low Volatility
- IndicatorValueSignal
- MFI63.01Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20190.01Bullish
- SMA 50190.40Bullish
- EMA 20200.73Bullish
- EMA 50197.42Bullish
- DEMA 20215.02Bullish
- DEMA 50193.14Bullish
- TEMA 20232.19Bullish
- TEMA 50190.41Bullish
- MACD13.15Bullish
- ADX27.59Strong Trend
- IndicatorValueSignal
- RSI65.36Neutral
- CCI182.11Overbought
- ROC 1447.54Bullish
- ROC 2538.04Bullish
- Stoch K81.28Overbought
- Stoch D81.45Overbought
- IndicatorValueSignal
- BB Upper242.21Overbought
- BB Middle190.01Neutral
- BB Lower137.81Neutral
- ATR19.60High Volatility
- IndicatorValueSignal
- MFI85.58Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6184.30Bullish
- SMA 12191.53Bullish
- SMA 24220.16Bullish
- EMA 6196.73Bullish
- EMA 12196.47Bullish
- EMA 24193.36Bullish
- DEMA 6204.95Bullish
- DEMA 12192.11Bullish
- DEMA 24212.63Bullish
- TEMA 6219.84Bullish
- TEMA 12188.38Bullish
- TEMA 24195.56Bullish
- MACD31.80Bearish
- ADX24.01Weak Trend
- IndicatorValueSignal
- RSI58.56Neutral
- CCI81.55Neutral
- ROC 2548.49Bullish
- ROC 50441.08Bullish
- Stoch K29.79Neutral
- Stoch D53.25Neutral
- IndicatorValueSignal
- BB Upper319.67Neutral
- BB Middle218.83Neutral
- BB Lower117.98Neutral
- ATR41.49High Volatility
- IndicatorValueSignal
- MFI61.78Neutral